Axogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
November 10 2021 - 7:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced that Karen Zaderej, chairman, CEO, and
president, will present at the Canaccord Genuity Virtual MedTech,
Diagnostics and Digital Health & Services Forum. The
presentation is scheduled for Thursday, November 18, 2021 at 10:00
a.m. ET.
The presentation will be webcast live and
accessible through the Investors page at www.axogeninc.com. For
those not available to listen to the live broadcast, a replay will
be archived for 90 days and available through the Investors page on
www.axogeninc.com.
About AxogenAxogen (AXGN) is the leading
company focused specifically on the science, development, and
commercialization of technologies for peripheral nerve regeneration
and repair. Axogen employees are passionate about helping to
restore peripheral nerve function and quality of life to patients
with physical damage or transection to peripheral nerves by
providing innovative, clinically proven, and economically effective
repair solutions for surgeons and health care providers. Peripheral
nerves provide the pathways for both motor and sensory signals
throughout the body. Every day, people suffer traumatic injuries or
undergo surgical procedures that impact the function of their
peripheral nerves. Physical damage to a peripheral nerve, or
the inability to properly reconnect peripheral nerves, can result
in the loss of muscle or organ function, the loss of sensory
feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard Nerve Connector®,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; and
Axoguard Nerve Cap®, a porcine submucosa ECM product used to
protect a peripheral nerve end and separate the nerve from the
surrounding environment to reduce the development of symptomatic or
painful neuroma. The Axogen portfolio of products is available in
the United States, Canada, the United Kingdom, South Korea, and
several other European and international countries.
Contact:Axogen, Inc.Peter J. Mariani, executive vice
president and chief financial
officerpmariani@axogeninc.comInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024